Expression and Significance of KL-6 in BALF and Serum of Patients with Idiopathic Pulmonary Fibrosis_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

ZhuChen , ZhaoYabin ,  KongLingfei , LiZhenhua , KangJian

Institute of Respiratory Diseases, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning, 110001, China;

Corresponding?author：

KongLingfei, Email: konglingf@sina.com

Keywords：

Idiopathic pulmonary fibrosis; Bronchoalveolar lavage fluid; Krebs von den lungen 6

DOI：

10.7507/1671-6205.2015058

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To detect the levels of Krebs von den lungen 6 (KL-6) in bronchoalveolar lavage fluid (BALF) and serum of patients with idiopathic pulmonary fibrosis (IPF),and explore its clinical significance. Methods Thirty-four patients with IPF and 10 patients with sarcoidosis in Ⅰ period were recruited in the study. ELISA was used to detect the level of KL-6 in BALF and serum. Results In the IPF group,the forced vital capacity as percentage of predicted value (FVC% pred) and diffusion capacity for carbon monoxide as percentage of predicted value (D_LCO %pred) were both significantly lower than those of the sarcoidosis group[(69.51±13.65)% vs. (82.06±5.84)%,(48.58±12.73)% vs. (81.47±6.39)%,P<0.01]. In the BALF of IPF group,the percentage of neutrophils was higher[(8.91±6.79)% vs. (5.50±3.60)%,P<0.05],and the percentages of lymphocytes and CD₄/CD₈ ratio were lower than those of the sarcoidosis group[(11.71±6.64)% vs. (23.30±12.68)%,(1.46±0.83) vs. (4.01±5.10),P<0.05]. In the IPF group,the level of KL-6 in the BALF and serum was higher than that of the arcoidosis group[(437.43±251.70) U/mL vs. (221.59±127.41) U/mL,(857.81±515.53) U/mL vs. (338.67±168.13) U/mL,P<0.001]. There was obvious correlation between the level of serum KL-6 with FVC%pred and D_LCO%pred in the IPF group (r=-0.46,r=-0.58,P<0.05). Conclusions The level of KL-6 in BALF and serum is elevated in patients with IPF. There is obvious correlation between the level of serum KL-6 with FVC%pred and D_LCO%pred in IPF patients. KL-6 may be an indicator of IPF in clinical diagnose.

Citation： ZhuChen, ZhaoYabin, KongLingfei, LiZhenhua, KangJian. Expression and Significance of KL-6 in BALF and Serum of Patients with Idiopathic Pulmonary Fibrosis. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(3): 225-228. doi: 10.7507/1671-6205.2015058 Copy

1.	?Panos RJ,Mortenson RL,Niccoli SA,et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis:causes and assessment. Am J Med,1990,88:396-404.
2.	Olson AL,Swigris JJ,Lezotte DC,et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med,2007,176:277-284.
3.	Kohno N,Kyoizumi S,Awaya Y,et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydratel antigen KL-6. Chest,1989,96:68-73.
4.	Ohshimo S,Yokoyama A,Hattori N,et al.KL-6,a human MUC1 mucin,promotes proliferation and survival of lung fibrosis.Biochem Biophys Res Commun,2005,338:1845-1852.
5.	Raghu G,Collard HR,Egan JJ,et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med,2011,183:788-824.
6.	中華醫學會呼吸病學分會.支氣管肺泡灌洗液細胞學檢測技術規范(草案).中華結核和呼吸雜志,2002,25:390-391.
7.	魏麗,馬艷良,高占成,等.黏蛋白和間質性肺疾病.中華結核和呼吸雜志,2012,35:700-702.
8.	Xu L,Yan DR,Zhu SL,et al. KL-6 regulated the expression of HGF,collagen and myofibroblastdifferentiation. Eur Rev Med Pharmacol Sci,2013,17:3073-3077.
9.	Kitamura S,Hiwada K,Kobayashi J,et al. Use of the ED046 kit to analyze serum KL-6 in patients with pneumonitis. Nihon Kyobu Shikkan Gakkai Zasshi,1996,34:639-645.
10.	Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest,1999,46:151-158.
11.	日本呼吸學會彌漫性肺疾患的診斷·治療指南編制委員會.特發性間質性肺病診斷和治療手冊. 日本呼吸器學會雜志,2011,43:179-207.

1. ?Panos RJ,Mortenson RL,Niccoli SA,et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis:causes and assessment. Am J Med,1990,88:396-404.
2. Olson AL,Swigris JJ,Lezotte DC,et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med,2007,176:277-284.
3. Kohno N,Kyoizumi S,Awaya Y,et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydratel antigen KL-6. Chest,1989,96:68-73.
4. Ohshimo S,Yokoyama A,Hattori N,et al.KL-6,a human MUC1 mucin,promotes proliferation and survival of lung fibrosis.Biochem Biophys Res Commun,2005,338:1845-1852.
5. Raghu G,Collard HR,Egan JJ,et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med,2011,183:788-824.
6. 中華醫學會呼吸病學分會.支氣管肺泡灌洗液細胞學檢測技術規范(草案).中華結核和呼吸雜志,2002,25:390-391.
7. 魏麗,馬艷良,高占成,等.黏蛋白和間質性肺疾病.中華結核和呼吸雜志,2012,35:700-702.
8. Xu L,Yan DR,Zhu SL,et al. KL-6 regulated the expression of HGF,collagen and myofibroblastdifferentiation. Eur Rev Med Pharmacol Sci,2013,17:3073-3077.
9. Kitamura S,Hiwada K,Kobayashi J,et al. Use of the ED046 kit to analyze serum KL-6 in patients with pneumonitis. Nihon Kyobu Shikkan Gakkai Zasshi,1996,34:639-645.
10. Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest,1999,46:151-158.
11. 日本呼吸學會彌漫性肺疾患的診斷·治療指南編制委員會.特發性間質性肺病診斷和治療手冊. 日本呼吸器學會雜志,2011,43:179-207.

Next Article
Clinical Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Chinese Journal of Respiratory and Critical Care Medicine

Expression and Significance of KL-6 in BALF and Serum of Patients with Idiopathic Pulmonary Fibrosis

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content